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Abstract: To bring insights into neurofibroma biochemistry, a comprehensive secretome 
analysis was performed on cultured human primary Schwann cells isolated from surgically 
resected plexiform neurofibroma and from normal nerve tissue. Using a combination of 
SDS-PAGE and high precision LC-MS/MS, 907 proteins were confidently identified in the 
conditioned media of Schwann cell cultures combined. Label free proteome profiling 
revealed consistent release of high levels of 22 proteins by the four biological replicates of 
NF1 Schwann cell cultures relative to the two normal Schwann cell cultures. Inversely, 9 
proteins displayed decreased levels in the conditioned media of NF1 relative to normal 
Schwann cells. The proteins with increased levels included proteins involved in cell 
growth, angiogenesis and complement pathway while proteins with decreased levels 
included those involved in cell adhesion, plasminogen pathway and extracellular matrix 
remodeling. Retinoic acid receptor responder protein-1 (RARRES1), previously described 
as an integral membrane tumor suppressor, was found exclusively secreted by NF1 
Schwann cells but not by normal Schwann cells. All-trans retinoic acid modulated 
secretion of RARRES1 in a dose dependent manner. This study shows altered secretion of 
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key proteins in NF1 derived Schwann cells. The potential implication of these proteins in 
neurofibroma biology is discussed. 
Keywords: plexiform neurofibroma; Schwann cells; secretome; retinoic acid receptor 
responder protein1 
 
1. Introduction 
Plexiform neurofibromas are benign peripheral nerve sheath tumors affecting 26 to 30% of patients 
diagnosed with neurofibromatosis type I (NF1) [1]. They are often present as large peripheral nerve 
neoplasms affecting the head, neck and/or lower back [2]. They are ultimately composed of 
uncharacterized cell type of the Schwann cell lineage origin intertwined with fibroblasts, mast cells 
and endothelial cells [3]. Though benign, these peripheral nerve tumors can be clinically debilitating 
depending on their size, location and infiltrative nature [4]. Furthermore, individuals with plexiform 
neurofibroma are at risk of developing malignant peripheral nerve sheath tumors (MPNSTs) which are 
more challenging to treat. The only effective treatment available today for plexiform neurofibroma is 
surgical resection [4,5]. Unfortunately, depending on the location and the infiltrative nature of the 
tumor masses, complete surgical resection remains a challenge often leading to recurrence of even 
larger tumor masses causing pain, disfigurement and physical impairment [5,6]. 
It is suggested that plexiform neurofibroma arise from Schwann cells that undergo loss of 
heterozygosity at the NF1 locus [7]. Schwann cells are of neural crest origin and play an important role 
in the development and maintenance of the peripheral nervous system [8]. They are involved in the 
myelination and insulation of neuronal axons as well as in the regeneration and trophic support for 
neurons. During the course of NF1 pathogenesis Schwann cells undergo biallelic inactivation at the 
NF1 locus leading to somatic inactivation of NF1 gene that encode for neurofibromine-1 protein, a 
physiological inhibitor of the Ras pathway [1,9]. This results in hyper-activation of the Ras pathway 
and uncontrolled proliferation of Schwann cells. 
Agents targeting the Ras pathway and kinase pathways showed promise in inhibiting neurofibroma 
progression in vitro and in mouse models [10]. Unfortunately, these same agents had little to no impact 
on patients with progressive plexiform neurofibroma indicating that Ras pathway alone does not 
account for the plexiform neurofibroma progression [11].  
Recent studies suggested involvement of the cell microenvironment and cell-cell interaction in 
neurofibroma progression [12,13]. Proteins secreted by both Schwann cells and mast cells might 
contribute to the uncontrolled growth of neurofibroma. Thus, a comprehensive study of secreted 
proteins or “secretome” of the implicated cells might be an attractive approach for identifying 
components that might bring insight into the molecular pathogenesis of NF1.  
In this study, we first sought to define the secretome of primary Schwann cell cultures derived from 
surgically resected plexiform neurofibroma. We used a label free proteome profiling strategy to 
systematically compare secretomes of four plexiform neurofibroma Schwann cell cultures to the 
secretome of normal Schwann cells derived from non-neoplastic peripheral nerve. This survey 
identified aberrant release of several key proteins by the plexiform neurofibroma Schwann cells 
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relative to the normal Schwann cells. Retinoic acid receptor responder protein 1 (RARRES1) also 
known as Tazarotene-induced gene (TIG1) was exclusively released by the plexiform neurofibroma 
Schwann cells and not by normal Schwann cells derived from non-noeplastic peripheral nerve.  
Identifying altered protein secretion by neurofiboma Schwann cells might shed light into the 
mechanism of neurofibroma progression and eventually define novel therapeutic targets for NF1 
patients suffering from recurrent plexiform neurofibroma. 
2. Results and Discussion 
2.1. Primary Schwann Cell Isolation and Culture  
NFSC141, NFSC142, NFSC143R and NFSC143L primary Schwann cells cultures were established 
from plexiform neurofibroma surgically resected from three different patients admitted at CNMC. 
NFSC143R and NFSC143L were established from tumors removed from the right and left lumbar of 
the same patient. Table 1 summarizes the age, gender and tumor location of the participating NF1 
patients. All three patients were diagnosed with a plexiform type of neurofibroma according to the 
pathology results. Established Schwann cell cultures from these specimens showed highly 
homogenous cell population. All NF1 Schwann cultures resembled the normal Schwann cell culture 
and expressed the characteristic Schwann cell marker S100β (Figure 1). The isolated cells were further 
subcultured to passage 2 and processed for secretome profiling and Western blot analysis and the 
results are described below. 
Table 1. Collected neurofibroma specimens used to establish Schwann cell cultures. 
Donor’s id Age (years) Gender Tumor location Diagnosis 
NFSC 141 20 Female Neck  Plexiform neurofibroma 
NFSC 142 19 Male Neck Plexiform neurofibroma 
NFSC 143R 17 Female Right lumbar Plexiform neurofibroma 
NFSC 143L Left lumbar Plexiform neurofibroma 
2.2. Secretome Profiling 
Secretome profiles of the four plexiform neurofibroma Schwann cell cultures NFSC141, NFSC142, 
NFSC143R and NFSC143L and the two normal primary human Schwann cell cultures NSC1 and 
NSC2 were obtained as described in the method using a combination of SDS-PAGE, in-gel digestion 
and high precision LC-MS/MS. We confidently identified and quantified 907 proteins in the CM of the 
four NF1 Schwann cell cultures and the two normal Schwann cell cultures combined (see 
Supplemental Table 1). Only proteins that were identified by at least two unique peptides and 
probability based score p value < 0.001 were retained for further analysis. In general Schwann cells 
were found to secrete a variety of extracellular matrix remodeling proteins, complement components, 
cell growth regulating proteins, cell adhesion and cell migration promoting proteins. 
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Figure 1. Human primary Schwann cell cultures maintained in vitro for 2 weeks in basal 
Schwann cell media. (a) Normal Schwann cells; (b) Schwann cells isolated from a 
plexiform neurofibroma of a 20 year old female donor (NFSC 141). Both cells were 
immuno-stained against the Schwann cell marker S100β protein shown in red and the 
nuclei with DAPI shown in blue. 
 
For quantitative comparisons we used ProteoIQ software to compare spectral counts and signal 
intensities generated from peptides belonging to each protein across all the samples analyzed. Several 
proteins were found uniquely secreted by NF1 Schwann cells and not by the normal Schwann cells and 
vice versa. Among these differentially secreted proteins, 12 were exclusively secreted by the four  
NF1 Schwann cell cultures and not by the normal Schwann cells, while 4 were exclusively secreted by 
the normal Schwann cells but not by any of the NF1 Schwann cell cultures. These proteins are reported 
in Table 2 with their spectral count, subcellular localization and potential function. NF1 Schwann  
cells secreted significant amounts of complement components C3 and C4-A, retinoic acid receptor 
responder protein1 (RARRES1), apolipoproteins D and E, Chitinase-3 like protein and glutathione 
peroxidase 3. The RARRES1 protein was among the most abundant proteins in this category  
with average spectral counts of 45 versus 0 in the CM of NF1 Schwann cells relative to normal 
Schwann cells. 
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Table 2. List of proteins that were uniquely secreted by the plexiform neurofibroma 
Schwann cells or by the normal Schwann cells. 
Accession n° Protein name NSC NFSCs 
Subcellular 
localization 
Function 
P49788 Retinoic acid receptor 
responder protein 1 
0 45 Single-pass 
membrane 
Tumor suppressor 
P01024 Complement C3 0 43 * secreted complement pathway 
P0C0L4 Complement C4-A 0 39 secreted Complement pathway 
P05090 Apolipoprotein D 0 15 secreted Transporter 
P22352 Glutathione peroxidase 3 0 10 * secreted Antioxidant 
P36222 Chitinase-3-like protein 1 0 11 * secreted unknown 
P55268 Laminin subunit beta-2 0 17 secreted Cell attachment 
P02649 Apolipoprotein E 0 7 * secreted Transporter 
Q4LDE5 Sushi, von Willebrand 
factor type A 
0 5 membrane/secreted Cell attachment 
Q92954 Proteoglycan 4 0 5 secreted Adhesion inhibition 
Q12805 EFEMP1 0 9 * secreted Cell 
adhesion/migration 
P02771 Alpha-fetoprotein  0 6 secreted Transporter  
P55285 Cadherin-6  16 0 Membrane/cell 
surface 
Cell adhesion 
P24844 Myosin regulatory light 
polypeptide 9 
12 0 cytoskeleton Cytokenesis and cell 
locomotion 
Q13308 Tyrosine-protein  
kinase-like 7 
11 0 cell surface Wnt signaling pathway 
P09104 Gamma-enolase 9 0 cytosol/membrane glycogenesis 
NSC: normal human primary Schwann cells; NFSCs: plexiform neurofibroma derived Schwann 
cells. Numbers represent the average spectral count detected in either normal human Schwann cell 
group (n = 2) or plexiform neurofibroma derived Schwann cell group (n = 4). * denote proteins that 
were secreted in 3 out of 4 NFSCs cultures; EFEMP1: EGF-containing fibulin-like extracellular 
matrix protein 1.  
Other proteins were secreted by both NF1 and normal Schwann cells but in different amounts. 
Secretion of 7 proteins were found to be increased by at least 3 fold with p value ≤ 0.05 while 6 were 
found to be decreased by at least the same factor and p value cut off in CM of NF1 Schwann cells 
relative to normal Schwann cells. These proteins are reported in Table 3 with their spectral counts, 
subcellular localization and potential function.  
Overall, plexiform neurofibroma Schwann cells released greater amounts of cell adhesion proteins 
such as laminin alpha 4, nidogen-2, cell growth regulating factors such as target of Nesh-SH3,  
EGF-containing fibulin-like extracellular matrix protein 1 and insulin-like growth factor binding 
proteins while dramatically decreased the release of receptor type tyrosine protein phosphatase kappa, a 
negative regulator of EGFR signaling as well as, plasminogen activator inhibitor 1 (PAI-1), chondroitin 
sulfate proteoglycan 4 (CSPG4), and integrin beta-1. 
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Table 3. List of proteins that were differentially secreted between the plexiform neurofibroma 
and the normal Schwann cell cultures. 
Accession n° Protein name NSC NFSCs 
Subcellular 
localization 
Function 
Q16363 Laminin subunit alpha-4 13 81 secreted cell 
attachment/migration 
Q14112 Nidogen-2  25 81 secreted  cell attachment 
/migration 
P05155 Plasma protease C1 inhibitor 7 85 secreted C1 complex inhibitor 
P07585 Decorin 12 67 secreted extracellular 
remodeling 
Q7Z7G0 Target of Nesh-SH3 1 19 secreted cell proliferation 
P98160 Perlecan 5 46 secreted  extracellular matrix 
remodeling 
P24592 Insulin-like growth  
factor-binding protein 6 
4 16 secreted regulates cell growth 
P05121 Plasminogen activator 
inhibitor 1 
727 284 secreted inhibitor of fibrinolysis 
P13611 Versican core protein 12 1 secreted intercellular signaling 
and connecting  
cells with the 
extracellular matrix 
Q6UVK1 Chondroitin sulfate 
proteoglycan 4  
83 19 Cell surface cell growth and 
migration 
Q15262 Receptor-type  
tyrosine-protein  
phosphatase kappa 
12 2 Cell surface Negative regulator  
of EGFR  
signaling pathway 
P05556 Integrin beta-1 13 1 Cell surface Cell adhesion 
NSC: normal human primary Schwann cells; NFSCs: plexiform neurofibroma derived Schwann 
cells. Numbers represent the average spectral count detected in either normal human Schwann cell 
group (n = 2) or plexiform neurofibroma derived Schwann cell group (n = 4).  
The altered secretome signature in NF1 Schwann cells relative to normal Schwann cells was 
maintained in the commercially available sNF96.2 cell line established from a malignant peripheral 
nerve sheath tumor that was surgically resected from a 27 year old donor five years ago [14] (see 
supplemental Table). Several proteins that were elevated or decreased in the CM of NF1 Schwann 
cells relative to normal Schwann cells maintained the same expression direction in the CM of sNF96.2 
cells relative to normal Schwann cells. These include the RARRES1 protein, Complements, chitinase 
3-like protein, alpha fetoprotein, cadherin-6 etc. (see supplemental Table) 
2.3. Characterization of Schwann Cell Secreted RARRES1 Protein 
An earlier study described RARRES1 protein as a 33 kDa single pass trans-membrane protein with 
a short N-terminal cytosolic domain, a transmembrane domain and a large C-terminal [15]. The secreted 
RARRES1 was identified by 12 unique tryptic peptides in SDS-PAGE bands ranging from 80 to  
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160 kDa with higher concentration around 110 kDa. This apparent mass is much higher than the 
expected 38–40 kDa molecular mass reported for the cell attached RARRES1 protein [15,16]. The 
commercially available sNF96.2 Schwann cell line established from MPNST also secreted similar high 
molecular mass RARRES1 protein. The sequences of the detected peptides for the extracellular 
RARRES1 and their position in the protein are shown in Figure 2. The observed masses for these 
peptides were within 10 ppm accuracy with confidence identification better than 99%. All 12 peptides 
belonged to the C-terminal extracellular domain of the protein suggesting possible shedding of 
RARRES1 from NF1 Schwann cells or secretion of a novel splice isoform. Interestingly, the 
commercially available rabbit polyclonal antibodies (from two different sources and with different 
target epitope) raised against cell attached RARRES1 failed to detect the secreted form of RARRES1 
(data not shown). This result suggests a potential posttranslational modification of the secreted 
RARRES1. 
Figure 2. Peptide mapping for the Schwann cell secreted RARRES1. (A) SDS-PAGE of 
total proteins collected in the conditioned medium of a primary NF-1 Schwann cell culture. 
The boxed area in the gel indicates where RARRES1 protein was detected by mass 
spectrometry analysis; (B) List of detected and identified tryptic peptides for the secreted 
RARRES1 protein with their expected and measured molecular masses and sequencing 
confidence; (C) Primary sequence of the RARRES1 protein with N-terminal cytosolic 
domain, integral membrane domain and the C-terminal extracellular domain. Detected and 
identified tryptic peptides for the secreted RARRES1 are highlighted in red and underlined. 
No tryptic peptide was detected for the integral membrane and the cytosolic domain.  
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2.4. mRNA RARRES Expression Levels in NF1 Versus Normal Schwann Cells 
2.4.1. Quantitative RTPCR  
Quantitative RTPCR targeting RARRES1 mRNA in total cell lysates showed a 150 fold higher 
level of RARRES1 expression in NF1 Schwann cells relative to normal Schwann cells (Figure 3). This 
data shows that the RARRES1 gene was actively expressed in plexiform neurofibroma Schwann cells 
compared to normal Schwann cells and correlates with the high levels of secreted RARRES1 protein 
seen in NF1 Schwann cells relative to normal Schwann cells. 
Figure 3. RTPCR analysis of the RARRES1 mRNA expression in NF1 and normal 
Schwann cell pellets. Left panel shows the RTPCR product obtained on mRNA prepared 
from normal Schwann cell culture (NSC) and plexiform neurofibroma Schwann cell 
culture (NFSC 142). Right panel shows the relative quantities of the RARRES1 mRNA 
levels in normal Schwann cells (NSC) and Schwann cells isolated from a plexiform 
neurofibroma of a 19 year old male (NFSC 142). Values are normalized to internal control 
GAPDH mRNA levels. 
 
2.4.2. Western Blot Analysis  
To verify if this high expression of RARRES1 mRNA in NF1 Schwann cells relative to normal 
Schwann cells translates into increased expression of the RARRES1 protein in the cell pellets we 
performed Western blot analysis on the total protein extracts from NF1 and normal Schwann cells using 
two different rabbit polyclonal antibodies against human RARRES1 protein. Unlike the secreted 
RARRES1, the cell attached form of the RARRES1 was detected as a single band around 40 kDa in 
agreement with the antibody manufacturer datasheet and with earlier studies [16]. However, there was 
no significant difference in the expression levels of the 40 kDa RARRES1 between the normal and 
NF1 Schwann cells (Figure 4). 
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Figure 4. Expression levels of cell attached RARRES1 in normal versus NF1 Schwann 
cells. Cell pellets were prepared from two normal Schwann cell culture (NSC and 
immortalized NSC) and five plexiform neurofibroma Schwann cell cultures (NFSCs). 
Expression levels of cell attached RARRES1 was examined in cell pellets using commercially 
available antibody. Lower panel show Western blot of a loading control GAPDH protein. 
 
2.5. All-Trans Retinoic Acid Induces Expression of Secreted RARRES1 
Since the commercially available RARRES1 antibodies failed to detect extracellular RARRES1 we 
synthesized a stable isotope labeled RARRES1 standard by culturing sNF96.2 cell line in medium 
where Arg and Lys were replaced by stable isotope labeled 13C6-Arg and 13C6, 15N2-Lys. All secreted 
proteins including RARRES1 protein were uniformly and fully labeled with 13C6-Arg and 13C6,  
15N2-Lys after 7 cell doublings. A fixed amount of the stable isotope labeled RARRES1 was then 
spiked into equal aliquots of conditioned media collected from unlabeled sNF96.2 cells treated for 24 
hours with 0, 0.25, 0.5 or 1 µM RA of all-trans retinoic acid (RA). Spiked samples were processed for 
mass spectrometry analysis as described in the method. Peptides generated from de novo synthesized 
RARRES1 protein and the labeled spiked-in RARRES1 proteins are detected as pairs of light and 
heavy ions. Figure 5a shows example spectra of heavy and light ion pairs corresponding to labeled and 
unlabeled RARRES1 tryptic peptide (YNPESLLQEGEGR) generated from labeled standard 
RARRES1 and de novo synthesized RARRES1. Figure 5b shows the overall expression levels of the 
cellular secreted RARRES1 by sNF96.2 treated with different doses of RA (the levels are relative to 
the spiked-in SILAC labeled standard RARRES1). While the expression levels of secreted RARRES1 
increased in a dose dependent manner in response to RA treatment with almost a 2-fold increase after 
24 hours incubation with 1 µM RA dose, the band detected by Western blot analysis for the cell 
attached RARRES1 remained unchanged following treatment of sNF96.2 cells with RA even at a 
higher dose of 1 µM of RA (Figure 5c).  
  
40 kDa RARRES1
GAPDH 
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Figure 5. Targeted mass spectrometry quantification of the secreted RARRES1 by 
sNF96.2 cells treated with different doses of all-trans retinoic acid. (a) MS spectra of 
doubly charged ions at m/z 758.92 and 761.92 for the unlabeled (U) and labeled (L) peptide 
(YNPESLLQEGEGR) generated from tryptic digest of the de novo synthesized RARRES1 
and the spiked-in labeled standard RARRES1 respectively. Spectra from the top to bottom 
are recorded for the same peptide pairs in function of different RA doses  
(0, 0.25, 0.5 and 1 µM). The intensity of the unlabeled peptide increases with increased 
doses of RA; (b) Bar graphs of the relative expression of de novo secreted RARRES1 in 
function of different RA concentrations. Standard deviations were obtained from 
measuring 4 unique peptide sequences of the RARRES1 protein (p-values < 0.05); (c) 
Western blot for the cell attached RARRES1 protein in function of RA treatment using a 
rabbit polyclonal antibody against human RARRES1 protein detecting a band around  
40 kDa. Note that while the extracellular RARRES1 increased by almost a factor of 2 
following treatment with 1 µM of RA for 24 hours the cellular attached RARRES1 
remained unchanged. 
 
2.6. Discussion 
Secretome profiling of human primary Schwann cell cultures revealed several key proteins that were 
differentially secreted between the plexiform neurofibroma derived Schwann cells and the non-neoplastic 
peripheral nerve derived Schwann cells. Most of these proteins are known to play a direct role in cell 
adhesion, cell proliferation and tumorigenesis. These include the target of Nesh-SH3 protein also 
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known as TARSH. This protein was approximately 19-fold higher in the CM of NF1 Schwann cells 
relative to normal Schwann cells. TARSH was recently described to play a role in cell senescence  
via the p53 pathway [17] but also play a major role in reducing cell dendritic complexity of neural 
cells [18]. This later function might be relevant to the differentiation of neural and Schwann cells in 
the context of neurofibroma progression. Further studies to define the role of TARSH in growth and 
differentiation of Schwann cells are needed.  
APOD was exclusively secreted by all four NF1 Schwann cells cultures and not by normal 
Schwann cells. This is in agreement with earlier studies showing that APOD mRNA levels were 
increased in neurofibroma compared to non-neoplastic peripheral nerve [19]. Interestingly, the same 
group showed that APOD mRNA levels decreases during transformation of benign neurofibroma to 
MPNSTs. The exact role of APOD in neurofibroma progression is however not well understood at 
present. Nevertheless expression of APOD was often found to be increased in soft tissue tumors and 
could as well have a direct role in growth of benign tumors [20]. 
Alpha-fetoprotein (AFP) is another interesting protein that was significantly elevated in the 
conditioned media of the four NF1 Schwann cell cultures compared to the normal Schwann cell 
cultures. AFP is a 70 kDa glycoprotein that is normally expressed during fetal development then repressed 
after birth [21]. Its reappearance often indicates the presence of a tumor especially hepatocellular 
carcinoma [22] but also other tumors of germ cell origin and gastrointestinal tract [23,24]. Furthermore, 
AFP was reported to promote proliferation of NIH 3T3 cells via activation of the Ras pathway [25]. 
These data suggests that AFP might be involved in the growth and proliferation of NF1 Schwann cells 
by acting in synergy with the inactive neurofibormin-1 thus resulting in hyperactivation of the Ras 
pathway. However, this hypothesis need to be further verified using mouse knockdown assays.  
The dramatic decrease of PAI-1 in the extracellular milieu of NF1 Schwann cells relative to normal 
Schwann cells is also highly significant in the context of neurofibroma growth and progression. Indeed, 
PAI-1 acts as a physiological inhibitor of urokinase-type plasminogen activator (uPA), a serine 
protease that promotes tumor progression and invasiveness [26]. An earlier study targeting the 
plasminogen activation pathway in cutaneous neurofibroma demonstrated that Schwann cells, and not 
other cells, in the neurofibroma tissue are responsible for the release of uPA and its regulator PAI-1 [27]. 
In this study we were not able to detect uPA in the secretome profiles of normal and NF1 Schwann 
cells but we detected a significant amount of uPA (7 spectral counts) in the conditioned medium of the 
malignant sNF96.2 Schwann cell line (see supplemental Table). This is in agreement with the 
malignancy of the sNF96.2 relative to the NF1 and normal Schwann cells studied herein.  
Other interesting proteins that were abundant in the extracellular milieu of NF1 Schwann cells 
relative to normal Schwann cells include the perlecan also known as basement membrane-specific 
heparan sulfate proteoglycan core protein, a secreted heparan sulfate glycoprotein involved in 
endothelial cell proliferation, mitogenesis and angiogenesis [28]. The high secretion of this protein by 
NF1 Schwann cell might contribute the complex growth and vasculature often seen in plexiform 
neurfibroma tissue. Furthermore NF1 Schwann cells secreted higher amounts of EFEMP1, an activator 
of the EGFR signaling [29] while decreasing the levels of the receptor-type tyrosine-protein phosphatase 
kappa, a negative regulator of EGFR signaling [30,31]. This suggests that EFGR signaling might be 
hyperactivated in NF1 Schwann cells relative to normal Schwann cells. However, this hypothesis 
needs to be verified in future studies. 
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Perhaps one of the most interesting findings in the secretome survey of Schwann cells is the 
exclusive secretion of a high molecular mass RARRES1 protein (~110 kDa) by the four NF1 Schwann 
cultures including the sNF96.2 cell line and not by the normal Schwann cell cultures. Secretion of 
RARRES1 protein is novel and to the best of our knowledge never been reported or discussed before. 
Whether the protein was proteolytically cleaved from the cell surface or was secreted as a splice 
isoform remains to be carefully examined. Nevertheless, all the RARRES1 tryptic peptides identified 
by mass spectrometry in the CM of NF1 Schwann cells belonged to the extracellular domain of the 
protein. No peptides of the N-terminal domain or the transmembrane domain were detected suggesting 
potential secretion or shedding of the RARRES1 protein.  
The RARRES1 gene was first characterized by Nagpal et al. [15] as a target gene that was induced 
in human cultured skin tissue by a synthetic retinoid Tazarotene, hence the name Tazarotene-induced 
gene 1 (TIG-1). The gene was suggested to express a 294 amino acid transmembrane protein with 
molecular mass of 33,285 Da. From the sequence it was predicted that RARRES1 is a single pass type 
II membrane protein with a short cytosolic N-terminal domain, a transmembrane domain and large 
extracellular C-terminal domain. In this study we found RARRES1 protein to be actually secreted or 
released in the extracellular milieu by NF1 Schwann cells. Interestingly, while RARRES1 protein 
extracted from the cell pellet was detected as a single band around 40 kDa by Western blot, the 
RARRES1 protein released into the CM by NF1 Schwann cells was detected in multiple bands ranging 
from 80 to 160 kDa with a highest concentration around 110 kDa. The antibody used to detect cell 
attached RARRES1 protein failed to detect the secreted RARRES1 even though several peptides were 
detected by mass spectrometry for this protein in the CM of cultured NF1 Schwan cells. This suggests 
that the released RARRES1 protein might be post-translationally modified hindering its detection by 
the antibody that detects the 40 kDa cell attached RARRES1. Based on the Uniprot knowledge 
database, human RARRES1 protein has only one potential N-glycosylation site which is not enough to 
explain or support the high increase in the molecular mass (up to 160 kDa) seen for extracellular 
RARRES1. Even though RARRES1 protein was previously detected in the conditioned media of some 
cancer cell lines [32,33] no details were provided regarding its molecular mass and its occurrence in 
the extracellular milieu. In this study we consistently detect secreted RARRES1 in bands ranging from 
80 to 160 kDa with the highest abundance around 110 kDa. All SDS-PAGE separations were 
performed under denaturing conditions thus ruling out the possibility of oligomerization. This 
significant increase in the molecular mass is typical for heparan sulfate modifications. However, future 
structural studies are needed to verify this hypothesis.  
Secretion of the high molecular mass RARRES1 protein was maintained in the sNF96.2 Schwann 
cell line previously established from an MPNST neurofibroma that was surgically resected from a 27 
year old donor five years ago [14]. We and others have examined secretomes of several human 
primary and tumor cell lines including retinal pigment epithelial cells [34,35], primary astrocytes, 
glioblastoma cell lines [36], twelve different types of human tumors cell lines [32], twenty three human 
carcinoma cells lines [33] and primary myotubes [37]. Of these cells only the Hela cell line, the colon 
cancer cell lines SW620 and Colo20 [33] and the lung carcinoma cell line A549 [32] secreted 
RARRES1 protein in their conditioned media. These data suggest that secretion of RARRES1 does 
occur and might be specific to certain cancer cell lines including our NF1 derived Schwann cells. 
Furthermore, close examination of the protein list identified in a secretome study of the omental 
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adipose tissue explant, also revealed the presence of RARRES1 protein in the conditioned medium 
[38]. In another independent study high expression levels of RARRES1 gene, up to 59-fold was 
observed in slowly proliferating mesenchymal stem cells derived from visceral adipose tissue versus 
highly proliferative mesenchymal stem cells derived from subcutaneous adipose [39]. It was suggested 
that RARRES1 might be involved in regulating proliferation as well as differentiation of adipose tissue 
derived mesenchymal stem cells. However, the authors did not distinguish between secreted 
RARRES1 or cell attached RARRES1 since measurements were performed at the mRNA levels. In 
summary, these data on the secretome studies of cancer cell lines, the adipose tissue explant and our 
current Schwann cell secretome strongly support the existence of a secreted form of the RARRES1 
protein. This secreted RARRES1 might play role in cell differentiation and growth.  
While this secreted RARRES1 protein seems to be increased in certain cancer cell lines, the 
attached RARRES1 protein was often reported to be less expressed, at least at the mRNA level, in 
prostate carcinoma, nasopharyngeal carcinoma and a leukemia cell line [40–42]. Others have shown 
that RARRES1 protein expression changes in function of cancer stage, with high expression at early 
stage then down-regulated at advanced stage [43]. The down-expression was often attributed to 
hypermethylation of the promoter region of the RARRES1 gene. In our study, even though the secreted 
RARRES1 was highly expressed in the NF1 Schwann cells relative to normal Schwann cells there was 
no significant difference in the expression levels of the 40 kDa cell attached RARRES1 between these 
cells. Additionally, treatment of sNF96.2 cells with increasing doses of all-trans retinoic resulted in 
increased secretion of the RARRES1 protein but not the 40 kDa cell attached RARRES1 protein. This 
suggests that these two forms of the RARRES1 protein might be posttranslationally regulated or 
originates from mRNA splicing that is tightly controlled in these Schwann cells. However this 
hypothesis remains to be carefully examined. 
The lower expression of cell attached RARRES1 in prostate and nasopharyngeal carcinoma has 
suggested that RARRES1 protein might act as a tumor suppressor. However, mechanisms by which 
RARRES1 inhibits cell proliferation in cancer are largely unknown. Recent studies have shown that 
RARRES1 is a potential inhibitor of the cytoplasmic carboxypeptidase AGBL2, a protein that is 
involved in the regulation of tubulin tyrosination and tumorigenesis [44]. Furthermore the same group 
showed that knockdown of RARRES1 in human prostatic epithelial cell line resulted in down-regulation 
of an enzyme involved in negative regulation of the growth hormone-stimulated signal transduction 
pathways with concomitant up-regulation of a tumor suppressor disks large 2 [16]. While this might be 
true for the cell attached RARRES1 the over expression of secreted RARRES1 in NF1 Schwann cells 
and other cancer cell lines remains intriguing and requires further investigation to define the role of 
secreted RARRES1 protein in the context of tumor cells. 
3. Experimental Section  
3.1. Specimen Collection 
Normal human primary Schwann cells were purchased from ScienCell Research Laboratories 
(Carlsbad, CA). The normal Schwann cells were isolated from spinal nerve of healthy donor according 
to the manufacturer and were cultured into two separate batches named as NSC1 and NSC2 herein. 
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The malignant sNF96.2 Schwann cell line was purchased from the American Type Culture Collection 
(ATCC; Manassas, VA, USA). Immortalized normal human Schwann cells were a gift from Vedant 
Arun and Dr. Guha of the University of Toronto Canada. All neurofibroma specimens and nerve tissue 
specimens were collected in house in accordance with an Institutional Review Board approved 
protocol at Children’s National Medical Center (CNMC) and after obtaining patients’ written informed 
consent. Only excess specimens after diagnosis were used in this study. Diagnosis was performed at 
the pathology clinic at CNMC by Dr. Ashley Hill and reported to us as de-identified information where 
only age, gender, diagnosis and tumor location were included (Table 1). Normal sural nerve tissue was 
gift from Dr. Ashley Hill and was collected postmortem from a 9 week old female donor. Normal 
sciatic nerve was obtained from the NICHD Brain and Tissue Bank of the University of Maryland 
Medical School. Aliquots from freshly resected tumor specimens were immediately placed in a sterile 
solution of serum free DMEM medium for subsequent Schwann cells isolation and cultivation as 
described below.  
3.2. Isolation and Culture of Human Primary Schwann Cells  
Collected fresh tissue from each patient was dissected into 2 × 2 mm2 pieces and placed in a Petri 
Dish containing 10 mL of DMEM media supplemented with 0.8 U/mL of dispase (Sigma-Aldrich,  
St. Louis, MO, USA) and 160 U/mL of collagenase-1 (Sigma-Aldrich, St. Louis, MO, USA) followed 
by incubation at 37 °C for 2–4 h. Media was collected and dissociated cells were pelleted by gentle 
centrifugation at 300× g for 10 min. Pelleted cells were re-suspended and cultured in basal Schwann 
Cell Medium (SCM) from ScienCell Research Laboratories (Carlsbad, CA, USA) supplemented with 
10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and 1% Schwann cell growth supplement 
(SCGS) containing BSA 10 µg, insulin 5 µg, PDGF 5 ng, FGF-2 5 ng, progesterone 20 nM, forskolin 
200 nM, T3 60 nM and PMA 20 nM. Growing cells were maintained and passaged using the same 
proprietary media. In parallel, primary human Schwann cells obtained from ScienCell Research 
Laboratories (Carlsbad, CA, USA) as well as sNF96.2 cell line were cultured using the same media 
and conditions. Growing Schwann cells were characterized by immunofluorescent staining using 
rabbit antibodies against human S-100β and p75 proteins. 
3.3. Secretome Profiling  
Both normal and plexiform neurofibroma derived Schwann cells as well as sNF96.2 cell line were 
grown to 80% confluences in the SCM media above then washed 6 times with sterile PBS (Invitrogen, 
Carlsbad, CA, USA) before incubation in serum free media for an additional 24 hours. Conditioned 
media (CM) were then collected, centrifuged at 300× g and the supernatant were further filtered 
through a 0.22 µm nylon filter (Millipore, Bedford, MA, USA) to remove any cell debris or floating 
cells. Aliquots (2 mL) from each collected CM were further concentrated by using a 3 kDa cutoff filter 
(Millipore Corp., Billerica, MA, USA) and processed for SDS-PAGE and mass spectrometry analysis. 
After the gel was stained (Bio-Safe Coomassie; Bio-Rad), each lane was sliced into 30 bands, and each 
band was in-gel digested with trypsin (Promega, Madison, WI, USA) and the resulting peptides 
analyzed by LC-MS/MS as described below. 
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3.4. Liquid Chromatography-Tandem Mass Spectrometry  
Concentrated peptides from each band were injected via an autosampler (6 μL) and loaded onto a 
Symmetry C18 trap column (5 μm, 300 μm i.d. × 23 mm, Waters, Milford, MA, USA) for 10 min at a 
flow rate of 10 μL/min, 100% A. The sample was subsequently separated by a C18 reverse-phase 
column (3.5 μm, 75 μm × 15 cm, LC Packings, Sunnyvale, CA, USA) at a flow rate of 250 nL/min 
using an Eksigent nano-HPLC system (Dublin, CA, USA). The mobile phases consisted of water with 
0.1% formic acid (A) and 90% acetonitrile (B). A 65 minute linear gradient from 5 to 60% B was 
employed. Eluted peptides were introduced into the mass spectrometer via a 10 μm silica tip (New 
Objective Inc., Ringoes, NJ, USA) adapted to a nano-electrospray source (Thermo Fisher Scientific). 
The spray voltage was set at 1.2 kV and the heated capillary at 200 °C. The LTQ-Orbitrap-XL 
(ThermoFisher Scientific) was operated in data-dependent mode with dynamic exclusion in which one 
cycle of experiments consisted of a full-MS in the Orbitrap (300–2000 m/z, resolution 30,000) survey 
scan and five subsequent MS/MS scans in the LTQ of the most intense peaks using collision-induced 
dissociation with the collision gas (helium) and normalized collision energy value set at 35%. 
3.5. Database Search and Quantification  
For protein identification we used the SEQUEST search engine [45] and for label free proteome 
profiling we used ProteoIQ software (Nusep, Bogart, GA, USA). Database search was performed 
against human SwissProt database (Version 198; EuropeanBioinformatics Institute: Cambridge, UK, 
2012) indexed with assumptions for fully enzymatic tryptic cleavage with two missed cleavages and 
possible 16 Da shift for oxidized Met. The search result was filtered using the following acceptance 
criteria: DeltaCn (ΔCn) > 0.08, a variable threshold of Xcorr vs charge state (Xcorr ≥ 1.9 for z = 1, 
Xcorr ≥ 2.5 for z = 2, and Xcorr ≥ 3.5 for z = 3) and with mass accuracy better than 10 ppm. SRFs 
search result files were uploaded into the ProteoIQ software for parsing and spectral counting. Median 
relative intensity was compared between cases and controls using a non-parametric Wilcoxon rank 
sum test. Significance was set at the p value ≤ 0.05 level and no adjustments for multiple testing  
were performed. 
3.6. Reverse-Transcription PCR 
Total RNA was extracted following standard protocol of TRIzol® RNA Reagents (Invitrogen). 
Genomic DNA contaminant was removed using DNA-free™ Kit (Ambion) containing RNase-free 
DNase I. Double-stranded cDNA was synthesized from 0.5 µg cleaned RNA with an olig-dT primer in 
a 20 µL Super Script III First-Stand Synthesis SuperMix reaction(Invitrogen) before further PCR or 
quantitative real-time PCR analyses. For the regular PCR, 3 µL supernatant was used as input DNA to 
process PCR reaction using GoTaq® Hot Start Green Master Mix (Promega). The denatured primers 
were designed to amplify human RARRES1 and the sequences are: forward: 5-GAGCAGAG 
TTCAGTGTGCATG-3 and reverse: 5-CAACAAGAGGATTACCTGCTTTACAAG-3. Actin was 
used as an internal normalization reference and the sequences are, forward, 5-GAAGAGCTA 
TGAGCTGCCTGAC-3 and reverse, 5-AGGTCTTTACGGATGTCAACGT-3. 10 µL of PCR reaction 
were illuminated in 2% Ethidium bromide containing agarose gel.  
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Quantitative real time PCR 1 µL cDNA was used for real-time PCR in a 25 µL reaction. Monoplex 
real-time PCR was conducted in a 96-well spectrofluorometric thermal cycler (ABI PRISM  
7900 Sequence detector system; Applied Biosystems). RARRES1 primers used for the real time PCR 
were chosen from PrimerBank as forward: 5-AGACAACAAGAGGATTACCTGCT-3 and reverse:  
5-GCTGACTATTTCCAAGGGGTTT-3. Actin was used as the internal normalization control. 
Fluorescence was monitored during every PCR cycle at the annealing or extension step and during  
the post-PCR temperature ramp. Fold changes were then measured according to manufacturer 
instructions (Invitrogen). 
3.7. Western Blot Analysis  
RARRES1 expression was examined in both Schwann cell pellets and tissue specimens. After 
collecting the conditioned media for secretome analysis the remaining cells were washed three times 
with PBS and collected by gently scrapping into PBS media then pelleted by centrifugation at 300× g 
for 5 min. Total proteins were extracted from cell pellets in RIPA buffer composed of 25 mM Tris-HCl 
(pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS (Thermo Scientific, 
Rockford, IL, USA). Equal amounts of total proteins (30 µg) from each sample were resuspended in 
equal volume of Laemmli buffer (Bio-Rad, Hercules, CA, USA). Proteins were separated by SDS-PAGE 
under reducing conditions and transferred to nitrocellulose membrane (GE Healthcare, Piscataway, NJ, 
USA) for Western blot analysis. Nonspecific binding sites were blocked with 5% milk (Bio-Rad) and 
membrane was incubated overnight with rabbit polyclonal antibody against human RARRES1 in 2.5% 
milk. We tested RARRES1 antibodies from two different companies: ab76530 from Abcam 
(Cambridge, MA, USA) and AF4255 from R&D Systems, Inc (Minneapolis, MN, USA). The next 
day, the membranes were rinsed with Tris buffer containing salt and Tween and incubated with goat 
anti-rabbit IgG (1:3K, Bio-Rad) conjugated with horseradish peroxidase. Immunoblots were visualized 
by chemiluminescence (GE Healthcare), and Ponceau red was used to control for protein loading. 
3.8. Effect of All-Trans Retinoic Acid on the sNF96.2 Secreted RARRES1  
Since the commercially available antibodies failed to detected and quantify secreted RARRES1, we 
synthesized stable isotope labeled RARRES1, to use as a standard, by culturing sNF96.2 cell line in 
DMEM culture media where 12C6-Arg and 12C6, 14N2-Lys were replaced by 13C6-Arg and 13C6, 15N2-Lys. 
After at least 7 cell doublings (roughly four passages), cellular proteins were uniformly labeled with 
these stable isotope-containing amino acids including secreted proteins. Cells were then washed  
6 times with serum free media and incubated for another 24 hours in stable isotope labeled serum free 
media supplemented with 13C6-Arg and 13C6, 15N2-Lys. Conditioned media containing stable isotope 
labeled proteins was collected, centrifuged at 1000 × g and further filtered through a 0.2 μm 
Polyethersulfone syringe filter (Corning Inc.) then concentrated using 3 kDa MWCO centrifugal 
filtration device (Millipore Corporation, Billerica, MA, USA). The concentrated conditioned media 
was assayed for total protein content using Bio-Rad protein assay kit and stored at −20 °C until use. In 
parallel, the same cell line sNF96.2 was cultured in regular DMEM media supplemented with 10% 
FBS (ATCC), 100 U/mL of penicillin, 100 μg/mL of streptomycin (Invitrogen, Gibco, Carlsbad, CA, 
USA), and 1 mM of sodium pyruvate (Sigma Aldrich, St. Louis, MO, USA). When cells reached  
Int. J. Mol. Sci. 2012, 13 9396 
 
 
80–90% confluence they were washed 6 times with serum free medium then incubated for another 24 
hours in serum free medium supplemented with various doses of all-trans retinoic acid (0, 0.25, 0.5 
and 1 µM). All-trans retinoic acid solution was freshly prepared in ethanol just before use. The 
untreated control cells were incubated with ethanol alone in serum free media for the same period of 
24 hours. Conditioned media from untreated and treated cells were collected, spiked with equal 
amounts of condition media containing stable isotope labeled RARRES1 protein and processed as 
described above for SDS-PAGE and LC-MS/MS analysis. Bands corresponding to RARRES1 protein 
were sliced, in-gel digested by trypsin and the resulting peptides were analyzed by LC-MS/MS as 
described above. RARRES1 tryptic peptides were detected as pairs of stable isotope labeled and 
unlabeled peptides generated from the reference stable isotope labeled RARRES1 protein and the 
unlabeled RARRES1 protein secreted by the RA treated or untreated sNF96.2 cell cultures 
respectively. For quantification of RARRES1 protein in treated and untreated cells we used IP2 
software, an integrated proteomic applications (http://integratedproteomics.com/) that uses the 
extracted ion chromatogram of labeled and unlabeled peptide pairs to determine the intensity ratios of 
light to heavy peptide and thus the relative quantities of secreted RARRES1 protein by RA treated and 
untreated sNF96.2 cells versus the spiked reference stable isotope labeled RARRES1 protein.  
4. Conclusions  
The secretome survey of cultured primary Schwann cells revealed differential secretion of several 
key proteins between NF1 derived Schwann cells and normal nerve derived Schwann cells. The 
majority of the differentially secreted proteins are involved in cell proliferation, adhesion and 
migration. Secretion of the tumor suppressor RARRES1 protein by NF1 is novel and merits further 
studies to characterize the structure and the function of this secreted RARRES1 protein. 
Defining the role of these differentially secreted proteins in the context of Schwann cell biology 
might bring insight into Schwann cell transformation and neurofibroma pathogenesis. This will help 
define novel therapeutic strategies to slowdown or stop plexiform neurofibroma progression in patients 
diagnosed with NF1.  
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